Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AXCELIS TECHNOLOGIES INCACLS · Entity 4152 | Director | February 17, 2021 | February 17, 2021 |
| ClearPoint Neuro, Inc.CLPT · Entity 2367 | Director | October 01, 2026 | October 03, 2026 |
| KORU Medical Systems, Inc.KRMD · Entity 6517 | Director · Chairman of the Board | October 01, 2026 | October 01, 2026 |
| Vyant Bio, Inc.VYNT · Entity 116415 | Director | January 17, 2023 | January 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AXCELIS TECHNOLOGIES INC
Report date February 17, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,354 |
Reported balance
After 2021-02-17 transaction · row 1
1 source rowRow 1 · 2021-02-17 · Sale · Disposed 6,881 · Balance 1,354 |
ClearPoint Neuro, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 132,004 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 993 · Balance 132,004 F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued pursuant to the issuer's Seventh Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at the closing price of the issuer's common stock at September 30, 2026.
KORU Medical Systems, Inc.
Report date October 01, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 239,836 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 7,679 · Balance 239,836 |
Vyant Bio, Inc.
Report date January 17, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 23,895 |
Reported balance
After 2023-01-17 transaction · row 1
1 source rowRow 1 · 2023-01-17 · Grant · Acquired 4,368 · Balance 23,895 F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | IndirectBy R. John Fletcher 2015 Revocable Trust | 6,060 |
Reported balance
Holding disclosure · report date 2023-01-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,060 |
Filing footnotes · ownership attribution and instrument terms
F1: On January 17, 2023, the Reporting Person was granted 4,368 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2024, so long as Reporting Person remains a director through that date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,666 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.75 · Expires 2032-04-26 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 4,266 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
SPECTRANETICS CORP
Report date August 09, 2017 · Filed August 11, 2017
Section 16 reporting ended · disclosed 2017-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| SPNC Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-08-09 transaction · row 1
1 source rowRow 1 · 2017-08-09 · Disposition to issuer · Disposed 141,697 · Balance 0 F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes. F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the terms of the Agreement and Plan of Merger, dated as of June 27, 2017, among the Company, Philips Holding USA Inc., a Delaware corporation, and HealthTech Merger Sub, Inc., a Delaware corporation (the "Merger Agreement") and the Offer (as defined in the Merger Agreement), each share of Company common stock other than the restricted common stock described in Note 2 was validly tendered for $38.50 per share in cash, without interest and less any required withholding taxes.
F2: Includes 4,780 shares of restricted common stock that, pursuant to their terms upon consummation of the Merger Agreement, were canceled at the Effective Time (as defined in the Merger Agreement) and converted into the right to receive $38.50 per share in cash, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 4, 2022 22:17 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,702 | $10.19 | $17,343.38 |
DisclosureSEC source: 0001285550-22-000063 · wf-form4_166492184686141.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,286 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $10.19 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending September 30, 2022. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:51 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 10,022 | $2.25 | $22,549.50 |
DisclosureSEC source: 0001161697-22-000493 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,985 Read SEC document |
| July 18, 2022 Filed Jul 29, 2022 20:56 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 4,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-020756 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,359 F1 · shares: On July 18, 2022, the Reporting Person was granted 4,696 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on July 18, 2023, so long as Reporting Person remains a director though that date. F1 · price: On July 18, 2022, the Reporting Person was granted 4,696 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on July 18, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 18:38 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,373 | $12.63 | $17,340.99 |
DisclosureSEC source: 0001285550-22-000031 · wf-form4_165713267692568.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,584 F1 · price: These shares were issued pursuant to the issuer's Fourth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $12.63 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ending June 30, 2022. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 22:13 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 9,003 | $2.50 | $22,507.50 |
DisclosureSEC source: 0001161697-22-000338 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,963 Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,179 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0001420506-22-001145 · doc4_1008.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Underlying: Common Stock · 6,179 shares Expires 2032-05-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:36 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 9,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001420506-22-001145 · doc4_1008.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,211 F1 · price: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2023 annual meeting of stockholders. Read SEC document |
| April 26, 2022 Filed Apr 26, 2022 16:16 UTC | OptiNose, Inc. OPTN · Entity 79464 | GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001494650-22-000045 · wf-form4_165100418529600.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2032-04-26 F1 · derivative.exercise_date: The option vests and becomes exercisable over a three-year period commencing on April 26, 2022. Thirty-three percent (33%) of the option vests and becomes exercisable on April 26, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining two years of the three-year period, subject to continued service with the Issuer. Read SEC document |
| April 18, 2022 Filed Apr 19, 2022 23:36 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 3,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-010476 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,663 F1 · shares: On April 18, 2022, the Reporting Person was granted 3,944 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on April 18, 2023, so long as Reporting Person remains a director though that date. F1 · price: On April 18, 2022, the Reporting Person was granted 3,944 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on April 18, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 21:03 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,741 | $9.96 | $17,340.36 |
DisclosureSEC source: 0001171520-22-000233 · eps10159.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,942 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $9.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2022. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:21 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 7,832 | $2.87 | $22,477.84 |
DisclosureSEC source: 0001161697-22-000159 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,960 Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 20:30 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 43,478 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-008834 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,875 F1 · shares: On March 30, 2022, the Reporting Person was granted 43,478 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2023, so long as Reporting Person remains a director though that date. F1 · price: On March 30, 2022, the Reporting Person was granted 43,478 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
| March 30, 2022 Filed Apr 13, 2022 21:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 24,844 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-009831 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,719 F1 · shares: On March 30, 2022, the Reporting Person was granted 24,844 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2023, so long as Reporting Person remains a director though that date. F1 · price: On March 30, 2022, the Reporting Person was granted 24,844 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 02:22 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock, $0.0001 par value | 3,721 | $1.31 | $4,874.51 |
DisclosureSEC source: 0001493152-22-001790 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,397 F1 · shares: On January 18, 2022, the Reporting Person was granted 3,721 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on January 17, 2023, so long as Reporting Person remains a director though that date. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 12:16 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,003 | $11.54 | $23,114.62 |
DisclosureSEC source: 0001171520-22-000013 · doc4_988.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,201 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $11.54 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2021. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:20 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 7,500 | $3.00 | $22,500.00 |
DisclosureSEC source: 0001161697-22-000010 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,128 Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:15 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 1,290 | $17.92 | $23,116.80 |
DisclosureSEC source: 0001420506-21-001362 · doc4_971.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,198 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $17.92 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended October 1, 2021. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 20:11 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 7,894 | $2.85 | $22,497.90 |
DisclosureSEC source: 0001161697-21-000468 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,628 Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 20:16 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 771 | $20.26 | $15,620.46 |
DisclosureSEC source: 0001420506-21-000843 · doc4_939.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,908 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $20.26 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2021. Read SEC document |
| June 30, 2021 Filed Jul 6, 2021 23:15 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,744 | $4.63 | $17,334.72 |
DisclosureSEC source: 0001161697-21-000328 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,734 Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 6,006 | $0.00 Strike: $19.98 | $0.00 |
DisclosureSEC source: 0001171520-21-000262 · ownership.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,006 Underlying: Common Stock · 6,006 shares Expires 2031-06-25 F2 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 12:33 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,003 | $0.00 | $0.00 |
DisclosureSEC source: 0001171520-21-000262 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,137 F1 · security: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. F1 · shares: The shares are restricted stock and will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2022 annual meeting of stockholders. Read SEC document |
| May 24, 2021 Filed May 24, 2021 20:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 15,300 | $3.39 | $51,834.87 |
DisclosureSEC source: 0001493152-21-012688 · ownership.xml · nonDerivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By R. John Fletcher 2015 Revocable Trust Disclosed balance after: 30,300 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.33 to $3.47 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 21, 2021 Filed May 24, 2021 20:05 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | PurchaseCommon Stock, $0.0001 par value | 15,000 | $3.33 | $49,948.50 |
DisclosureSEC source: 0001493152-21-012688 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By R. John Fletcher 2015 Revocable Trust Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.31 to $3.34 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 17, 2021 Filed May 18, 2021 20:17 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | PurchaseCommon Stock | 25,000 | $4.30 | $107,500.00 |
DisclosureSEC source: 0001161697-21-000267 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,990 Read SEC document |
| March 31, 2021 Filed Apr 5, 2021 20:31 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,551 | $3.52 | $12,499.52 |
DisclosureSEC source: 0001161697-21-000198 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,990 Read SEC document |
| March 31, 2021 Filed Apr 12, 2021 20:18 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 738 | $19.57 | $14,442.66 |
DisclosureSEC source: 0001420506-21-000402 · doc4_916.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,134 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $19.57 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended March 31, 2021. Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:48 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantStock option (right to buy) · Derivative | 13,015 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0001493152-21-007825 · ownership.xml · derivative · entry 3 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,015 Underlying: Common Stock · 13,015 shares Expires 2031-03-30 Read SEC document |
| March 30, 2021 Filed Apr 2, 2021 01:48 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | OtherStock option (right to buy) · Derivative | 10,265 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-21-007825 · ownership.xml · derivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,265 Underlying: Common Stock · 10,265 shares Expires 2030-08-01 F2 · kind: Pursuant to that certain Agreement and Plan of Merger, dated as of August 21, 2020, as amended, by and among Cancer Genetics, Inc. now known as Vyant Bio, Inc. ("Issuer"), CGI Acquisition, Inc., a Minnesota corporation and a wholly-owned subsidiary of Issuer ("Merger Sub") and StemoniX, Inc., a Minnesota corporation ("StemoniX") (the "Merger Agreement"), Reporting Person received options to purchase shares of Common Stock of the Issuer in exchange for options to purchase shares of StemoniX common stock, $0.0001 owned prior to the merger. These options are fully vested. Read SEC document |
| March 25, 2021 Filed Apr 2, 2021 01:48 UTC | Vyant Bio, Inc. VYNT · Entity 116415 | GrantCommon Stock | 8,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-007825 · ownership.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,676 F1 · shares: On March 30, 2021, the Reporting Person was granted 8,676 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2022, so long as Reporting Person remains a director though that date. F1 · price: On March 30, 2021, the Reporting Person was granted 8,676 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units fully vest on March 30, 2022, so long as Reporting Person remains a director though that date. Read SEC document |
| February 17, 2021 Filed Feb 17, 2021 22:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 6,881 | $39.00 | $268,359.00 |
DisclosureSEC source: 0001209191-21-011356 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354 Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 00:53 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 3,114 | $6.02 | $18,746.28 |
DisclosureSEC source: 0001161697-21-000035 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,439 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 23:37 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 808 | $15.00 | $12,120.00 |
DisclosureSEC source: 0001420506-21-000011 · doc4_895.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,396 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $15.00 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2020. Read SEC document |
| December 01, 2020 Filed Dec 1, 2020 19:42 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | PurchaseCommon Stock | 1,275 | $4.53 | $5,775.75 |
DisclosureSEC source: 0001161697-20-000508 · form_4.xml · nonDerivative · entry 2 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,325 Read SEC document |
| November 30, 2020 Filed Dec 1, 2020 19:42 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | PurchaseCommon Stock | 21,052 | $4.48 | $94,312.96 |
DisclosureSEC source: 0001161697-20-000508 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,050 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:07 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,124 | $5.71 | $12,128.04 |
DisclosureSEC source: 0001420506-20-001030 · doc4_853.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,588 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 22:06 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 2,124 | $5.71 | $12,128.04 |
DisclosureSEC source: 0001420506-20-001027 · doc4_853.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,588 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $5.71 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended September 30, 2020. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:12 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 2,597 | $7.22 | $18,750.34 |
DisclosureSEC source: 0001161697-20-000428 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,998 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 00:09 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 2,088 | $8.98 | $18,750.24 |
DisclosureSEC source: 0001161697-20-000285 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,401 Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 17:30 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,411 | $3.55 | $12,109.05 |
DisclosureSEC source: 0001171520-20-000283 · doc4_813.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,464 F1 · price: These shares were issued pursuant to the issuer's Third Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $3.55 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended June 30, 2020. Read SEC document |
| June 03, 2020 Filed Jun 17, 2020 20:16 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001420506-20-000697 · doc4_807.xml · derivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: The shares subject to this option will vest in full on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2021 annual meeting of stockholders. Read SEC document |
| May 28, 2020 Filed May 29, 2020 23:04 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | SaleCommon Stock | 50,750 | $26.52 | $1,345,890.00 |
DisclosureSEC source: 0001209191-20-033055 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,235 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $27.34, inclusive. The reporting person undertakes to provide to Axcelis Technologies, Inc., any security holder of Axcelis Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F2 · balance_after: Of the shares held as of May 28, 2020, 6,881 were issuable on vesting of restricted stock units granted to the director under the 2012 Equity Incentive Plan and are subject to forfeiture. Read SEC document |
| May 15, 2020 Filed May 15, 2020 12:50 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | GrantCommon Stock | 6,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-029476 · doc4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,985 F1 · price: These shares are issuable on vesting of restricted stock units granted under the Company's 2012 Equity Incentive Plan. Assuming continuation of service on the Board of Directors, these restricted stock units will vest on November 15, 2020. F2 · balance_after: Of the shares held as of May 15, 2020, 6,881 were issuable on vesting of restricted stock units granted to the director under the 2012 Equity Incentive Plan and are subject to forfeiture. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:50 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 2,500 | $7.50 | $18,750.00 |
DisclosureSEC source: 0001161697-20-000138 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,313 Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 20:11 UTC | ClearPoint Neuro, Inc. CLPT · Entity 2367 | GrantCommon Stock | 3,396 | $3.57 | $12,123.72 |
DisclosureSEC source: 0001420506-20-000359 · doc4_795.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,053 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 21:52 UTC | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 1,914 | $6.53 | $12,498.42 |
DisclosureSEC source: 0001161697-20-000007 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,856 Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:05 UTC | ClearPoint Neuro, Inc. MRIC · Entity 2367 | GrantCommon Stock | 2,445 | $4.96 | $12,127.20 |
DisclosureSEC source: 0001420506-20-000009 · doc4_782.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,657 F1 · price: These shares were issued pursuant to the issuer's Second Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to the reporting person under the issuer's Non-Employee Director Compensation Plan, as amended and restated. The shares were issued at a price of $4.96 per share, representing the volume-weighted average price of the issuer's common stock for the five-trading day period ended December 31, 2019. Read SEC document |
| December 31, 2019 Filed Jan 9, 2020 22:43 UTC Amendment | KORU Medical Systems, Inc. KRMD · Entity 6517 | GrantCommon Stock | 2,871 | $6.53 | $18,747.63 |
DisclosureSEC source: 0001161697-20-000028 · form_4.xml · nonDerivative · entry 1 FLETCHER R JOHN · CIK 0001215024 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,813 Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 21:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001209191-19-060205 · doc4.xml · derivative · entry 5 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2019 Filed Dec 12, 2019 21:11 UTC | AXCELIS TECHNOLOGIES INC ACLS · Entity 4152 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-19-060205 · doc4.xml · derivative · entry 4 FLETCHER R JOHN · CIK 0001215024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.